交易中 09-30 11:06:25 美东时间
+0.730
+14.09%
今日重点评级关注:HC Wainwright & Co.:维持GoldMining"买入"评级,目标价从3.25美元升至3.75美元;摩根士丹利:维持Crinetics Pharmaceuticals"超配"评级,目标价从65美元升至77美元
今天 14:16
Alpha Edge Media, a subsidiary of Aether Holdings, acquired WhaleTales, a crypto-focused newsletter, to expand its digital asset coverage. WhaleTales provides weekly crypto news, regulatory updates, and market analysis to over 40,000 subscribers. This purchase follows the acquisition of AltcoinInvesting.co, strengthening Aether’s position in the crypto sector and aligning with its strategy to build a multi-asset financial media platform. WhaleTal...
09-25 12:30
Athira Pharma announced a 10-for-1 reverse stock split to increase its share price, aiming to meet Nasdaq's $1.00 minimum bid price requirement and improve liquidity and investor interest. The split will take effect on September 17, 2025, with shares trading under the new adjusted price from September 18. Each 10 shares will combine into 1, reducing the total authorized shares from 900 million to 90 million. Fractional shares will be paid in cash...
09-11 13:00
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — Aether Holdings, Inc. (Nasdaq: ATHR) announced the expansion of its Alpha Edge Media™ division with the launch of six new branded newsletters covering equities, IPOs, small-caps, digital assets, and investor communities, along with its flagship Alpha Edge Summit™. These publications aim to grow a free and eventually paid subscriber base while providing critical data to support Aether Labs' AI models. The...
08-27 12:30
Alpha Edge Media, Inc. will host the Alpha Edge Summit Hong Kong 2025 on August 27, 2025, at Cloud 39, The Henderson building in Hong Kong. This exclusive event, themed "Where Alpha Meets Access: Institutional Strategies for a Digital Financial Future," will bring together over 200 influential digital asset investors, venture capitalists, blockchain innovators, and media voices during Bitcoin Asia Week. The summit features keynote addresses, pane...
08-20 12:30
Aether Holdings (NASDAQ:ATHR) reported quarterly losses of $(0.08) per share. This is a 166.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported $342.411 thousand in
08-20 05:44
Athira Pharma presented Phase 1 trial results for ATH-1105, a novel small molecule targeting neurodegenerative diseases like ALS, at the ALS Nexus 2025 conference. The trial, involving 80 healthy volunteers, demonstrated favorable safety, tolerability, and CNS penetration, supporting further development of the drug candidate. ATH-1105 aims to modulate the neurotrophic HGF system to restore neuronal health. The company highlighted the potential of...
08-14 11:00
<p style="font-family: Arial, sans-serif;"> Athira Pharma reported positive Phase 1 clinical trial results for ATH-1105, showing favorable safety, tolerability, and CNS penetration, supporting its development for ALS. The company paused fosgonimeton's development and is exploring strategic alternatives. Financials showed reduced cash, lower R&D and G&A expenses, and a narrowed net loss. </p>
08-07 20:05
计划长期储备比特币,MFH飙涨超50%;公司获高额溢价收购,CIO大涨超24%;与甲骨文达成供电合作,BE大涨23%>>
07-25 19:50
Aether Holdings (NASDAQ:ATHR) has commenced an underwritten public offering of units with expected gross proceeds of about $40 million. Aether expects to use approximately 85% of the net proceeds from...
07-21 20:33